Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on the development of novel, proprietary therapeutics based on
hypoxia-inducible factor (HIF) biology and the commercialization of
these products for patients with kidney disease, today announced
financial results for the second quarter ended June 30, 2014.
DANBURY, CT--(Marketwired - August 11, 2014) - Biodel Inc. (NASDAQ: BIOD) announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog ®
Mix 75/25 and Humulin ® R U-500 in patients with type 2 diabetes with moderate insulin resistance who use between 50 and 200 units of insulin per day.
Sign-up for Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized Meals Compared to Marketed Insulins in a Phase 2 Clinical Trial in Patients With Type 2 Diabetes investment picks
Corporation (NASDAQ:BIRT), The BIRT Company™ and leader in
personalized analytics and insights, today announced BIRT
PowerDocs™ is available for the Salesforce1 Mobile App, empowering
companies to run their business from their phone.
Dex Media, Inc. (NASDAQ:DXM), one of the largest national providers of
social, local and mobile marketing solutions through direct
relationships with local businesses, today announced financial results
for the second quarter and six months ending June 30, 2014.
Announced $352.5 Million Marcellus Acquisition Total Revenue Increases 14% to $35.0 Million Net income Increases 17% to $10.8 Million, or $0.15 per Diluted Share Oil Production Increases 8% to approximately 281,000 barrels Gas Production Increases 2% to approximately 1.63 Bcf EBITDA * Increases 1% to $21.9 Million
NEW YORK, Aug.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.